This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    IPX066-B11-01
Previous Study | Return to List | Next Study

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

This study has been completed.
Sponsor:
Collaborator:
Michael J. Fox Foundation for Parkinson's Research
Information provided by (Responsible Party):
IMPAX Laboratories, Inc.
ClinicalTrials.gov Identifier:
NCT01411137
First received: August 4, 2011
Last updated: April 18, 2017
Last verified: April 2017
August 4, 2011
April 18, 2017
August 2011
March 2013   (Final data collection date for primary outcome measure)
  • Patient Global Impression (PGI) [ Time Frame: 6 months ]
    At Part 1 Week 6, Part 2 Month 3 and Month 6 or at Early Termination, the subjects rated the change in their condition with IPX066 treatment from their condition prior to Part 1 Visit 1(Baseline) using Patient Global Impression (PGI) 7-point scale. 1=very much worse and 7=very much improved.
  • Clinical Global Impression (CGI) [ Time Frame: 6 months ]

    Clinician-reported satisfaction outcome of IPX066 using Clinical Global Impression (PGI) 7-point scale.

    At Part 1 Week 6; Part 2 Month 3, and Month 6 or at Early Termination, the Investigator rated how much a subject's overall condition had changed since Part 1 Visit 1 (Baseline) using 7-point scale. 1=very much worse and 7=very much improved.

  • Parkinson's Disease Questionnaire-8 (PDQ-8) [ Time Frame: 6 months ]
    Change from Baseline in Parkinson's disease Questionnaire-8 (PDQ-8) at End of Study or early discontinuation. The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms, each item ranging from 0 to 4, and the responses consist of 0=Never, 1=Occasionally, 2=Sometimes, 3=Often, and 4=Always or cannot do at all, total score ranging from 0 (never have problems/issues) to 32 (always have problems or cannot do at all).
  • Patient Global Impression [ Time Frame: 6 months ]
    Patient reported outcome
  • Clinical Global Impression [ Time Frame: 6 months ]
    Clinician reported outcome
  • Parkinson's Disease Questionnaire-8 (PDQ-8) [ Time Frame: 6 months ]
    Disease severity questionnaire
Complete list of historical versions of study NCT01411137 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD

The study had three distinct parts and is described as follows:

Part 1:

  • To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD
  • To evaluate the utility of the Objective Parkinson's Disease Measurement (OPDM), an exploratory computer-based system, in assessing dexterity and mobility in a subset of PD subjects.

Part 2:

• To evaluate the long-term safety and clinical utility of IPX066 under open-label conditions in eligible subjects who successfully completed Part 1 of the study.

Part 3:

• To further evaluate the long-term safety of IPX066 in eligible subjects who successfully completed Part 2.

Part 1: This study was a multicenter, open-label study. Subjects were to be converted from their previous CD-LD treatment to IPX066 over a 6-week period. Up to 40 subjects were to be enrolled in the study. Enrollment was defined as subjects who received study drug in Part 1 - Visit 1. Subjects were to be entered into one of two cohorts.

Approximately 24 subjects were to enroll in Cohort 1 (non-OPDM subjects) and up to 16 subjects at selected sites were to enroll in Cohort 2 (OPDM subjects). For the subjects enrolled in Cohort 2, along with the OPDM measurements, PK blood samples were also to be collected.

Part 2: Following the successful completion of Part 1 of the study, eligible subjects could participate in Part 2, a 6-month open-label extension study.

Part 3: Following the successful completion of Part 2 of the study, eligible subjects could participate in Part 3, an additional 6-month open-label extension study.

Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Parkinson's Disease
Drug: IPX066

Subjects were converted from their current treatment to IPX066 over a 6-week period.

Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules

Other Name: ER CD-LD
Experimental: IPX066
Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
Intervention: Drug: IPX066
Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci. 2017 Feb 15;373:116-123. doi: 10.1016/j.jns.2016.11.047. Epub 2016 Nov 23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
43
March 2013
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosed with idiopathic PD without any known cause for Parkinsonism.
  2. At least 30 years old at the time of PD diagnosis.
  3. Currently being treated with:

    • an LD dosing frequency of at least four times a day
    • at least one dose of CD-LD ER daily
    • requiring a total daily LD dose of at least 400 mg
    • stable regimen for at least 4 weeks prior to Screening
  4. Concomitant therapy with amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists is allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.
  5. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.

Exclusion Criteria:

  1. Pregnant or breastfeeding
  2. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.
  3. Nonresponsive to LD therapy.
  4. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.
  5. Planning to take during participation in the clinical study: any controlled-release LD product, additional CD or benserazide, entacapone or tolcapone, nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.
  6. Any evidence of suicidal behavior within 6 months of entering the study.
  7. Allergic or hypersensitive to to CD, LD, entacapone, riboflavin, Yellow Dye #5 (tartrazine), citrus fruit or grape juice.
  8. History of or currently active psychosis.
  9. Active or history of peptic ulcers or surgical procedure of the stomach, the small intestine or the large intestine.
  10. Active or history of narrow-angle glaucoma.
  11. History of malignant melanoma or a suspicious undiagnosed skin lesion.
  12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.
  13. Abnormal kidney function
  14. Severe hepatic impairment.
  15. Received any investigational medications during the 4 weeks prior to Screening.
  16. Previously enrolled in IPX066 studies.
Sexes Eligible for Study: All
30 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01411137
IPX066-B11-01
No
Not Provided
No
Not Provided
IMPAX Laboratories, Inc.
IMPAX Laboratories, Inc.
Michael J. Fox Foundation for Parkinson's Research
Study Chair: Impax Study Director Impax Pharmaceuticals Division (Impax) , a Division of Impax Laboratories Inc.
IMPAX Laboratories, Inc.
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP